Financials

	2022	2023
Net sales	-	-
Net income	-71.18M -61.05M -57.01M -52.31M -98.36M -6.8B -99.98M -673M -263M -3.41B -267M -261M -11.28B	-69.66M -59.76M -55.8M -51.2M -96.27M -6.66B -97.86M -658M -258M -3.34B -262M -256M -11.04B
Net Debt	-165M -141M -132M -121M -228M -15.75B -231M -1.56B -610M -7.9B -619M -605M -26.11B	-127M -109M -102M -93.28M -175M -12.13B -178M -1.2B -470M -6.08B -477M -466M -20.12B

* Estimated data More financial data

Company Profile

Achilles Therapeutics plc is a United Kingdom-based company engaged in the process of voluntary liquidation. The Company is not engaged in any business activity.

Employees

210

Sector

Investment Holding Companies

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq 16:00:00 2025-03-20 EDT			5-day change	1st Jan Change
1.480 ^USD	+0.68%		-.--%	-

25-03-20	Achilles Therapeutics plc Announces Board Changes	CI
25-03-19	Achilles Therapeutics plc(NasdaqCM:ACHL) dropped from NASDAQ Composite Index	CI

Market Cap	46.85M 40.19M 37.53M 34.43M 64.75M 4.48B 65.82M 443M 173M 2.25B 176M 172M 7.43B	P/E 2022	-0.49x	P/E 2023	-0.51x
Enterprise Value	-80.07M -68.68M -64.14M -58.84M -111M -7.65B -112M -757M -296M -3.84B -301M -294M -12.69B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	93.49%	Yield 2022 *	-	Yield 2023	-

25-03-20	Achilles Therapeutics plc Announces Board Changes	CI
25-03-19	Achilles Therapeutics plc(NasdaqCM:ACHL) dropped from NASDAQ Composite Index	CI
25-02-05	Syncona Portfolio Company Achilles Therapeutics to Pursue Voluntary Liquidation	MT
25-02-04	Achilles Therapeutics plc Announces Principal Executive Office Changes	CI
25-02-04	Sergio Quezada Steps Down as Chief Scientific Officer of the Achilles Therapeutics plc	CI
25-01-06	Achilles Therapeutics plc Announces Board Resignations	CI
24-12-27	Stocks seen down as holiday sales stabilise	AN
24-12-24	Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million	DJ
24-12-24	Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million, Concluding Strategic Review; Shares Up	MT
24-12-23	AstraZeneca PLC acquired Technology Assets of Achilles Therapeutics plc for $12 million.	CI
24-11-14	Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-22	Scancell Holdings plc Appoints Dr Phil L'huillier as Board Member, Effective 18 November 2024	CI
24-09-23	European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading	MT

24-04-05	Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	MT
24-04-05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT
23-12-14	BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	MT
23-05-11	Chardan Trims Price Target on Achilles Therapeutics to $11 From $12, Keeps Buy Rating	MT
23-03-08	Chardan Adjusts Price Target on Achilles Therapeutics to $12 From $17, Keeps Buy Rating	MT

Achilles Therapeutics plc Stock

Stocks

ACHL

US00449L1026

Investment Holding Companies

Valuation: Achilles Therapeutics plc

Latest news : Achilles Therapeutics plc

Analysts' recommendations: Achilles Therapeutics plc

Press Releases: Achilles Therapeutics plc

Quotes and Performance

Course Extremes

Managers and Directors: Achilles Therapeutics plc

Shell Companies

Financials

Company Profile

Income Statement and Estimates

25-02-28	Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration	AQ
24-12-27	Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca	AQ
24-12-26	Achilles Therapeutics : Announces Sale of Technology Assets to AstraZeneca Form 6 K	PU
24-12-24	Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca	AQ
24-12-02	Achilles Therapeutics : Information Contained in this Report on Form 6 K Form 6 K	PU

Manager	Title	Age	Since
Iraj Ali CEO	Chief Executive Officer	50	2017-12-31
Robert Coutts DFI	Director of Finance/CFO	42	2020-10-31
Matilde Saggese CTO	Chief Tech/Sci/R&D Officer	-	2021-02-28

Director	Title	Age	Since
Iraj Ali BRD	Director/Board Member	50	2017-12-31
Edwin Moses CHM	Chairman	71	-
Carsten Boess BRD	Director/Board Member	59	2020-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACHILLES THERAPEUTICS PLC	+0.68%	-.--%	-.--%	+57.24%	60.83M
CHURCHILL CAPITAL CORP XI	-6.71%	-9.82%	-	-	813M
CENTIEL AG	-3.24%	-4.65%	+297.58%	-71.97%	668M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	-0.10%	-	-	645M
CHURCHILL CAPITAL CORP XII	-0.74%	0.00%	-	-	595M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.59%	+0.59%	-	-	602M
CANTOR EQUITY PARTNERS IV, INC.	-0.10%	-0.29%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.26%	-0.86%	-	-	569M
CHURCHILL CAPITAL CORP XIII	-0.10%	-0.38%	-	-	507M
Average	-1.10%	-1.25%	+148.79%	-7.36%	561.47M
Weighted average by Cap.	-1.57%	-2.26%	+272.75%	-61.19%

3 years	0.63	1.76
5 years	0.63	9
10 years	0.63	18.95